Method for reducing blood insulin levels by reducing in vivo cathepsin L activity
US6620844B2 · kind B2 · utility
0Cited by
2References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2001 |
| Grant date | Sep 16, 2003 |
| Priority date | — |
| Expiry date | Feb 14, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions are provided for modulating blood insulin levels of animals by targeting the gene and gene products of cathepsins, particularly cathepsins L, K, and S, and especially cathepsin L. The method comprises: administering to the animal an agent that reduces an in vivo level of cathepsin L activity such that the blood insulin level of the animal is reduced. The method can be used to treat hyperinsulinmia and related diseases such as insulin resistance, type II diabetes, and hyperglycermia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.